Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.350 -0.150 (-1.58%)
Streaming Delayed Price Updated: 1:57 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
7 Analysts Have This To Say About Vir Biotechnology ↗
 
Via Benzinga
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment ↗
The company is working to engage the immune system to attack cancer cells. 
Via Investor's Business Daily
News headline image
What's Next: Vir Biotechnology's Earnings Preview ↗
 
Via Benzinga
News headline image
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why ↗
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why ↗
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies. 
Via Benzinga
News headline image
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
News headline image
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? ↗
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens. 
Via Benzinga
News headline image
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
What You Missed On Wall Street This Past Friday ↗
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
News headline image
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
From Vir Biotechnology Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.